Emergence of Dalbavancin, Vancomycin, and Daptomycin Nonsusceptible Staphylococcus aureus in a Patient Treated With Dalbavancin: Case Report and Isolate Characterization.

Zhang, Rutan; Polenakovik, Hari; Barreras Beltran, Ismael A; Waalkes, Adam; Salipante, Stephen J; Xu, Libin; Werth, Brian J · Clin Infect Dis · 2022

case_report · Level V

Where this comes from

Abstract

A patient with end-stage renal disease received 2 doses of dalbavancin for methicillin-resistant Staphylococcus aureus (MRSA) arteriovenous fistula infection and presented 5 weeks later with infective endocarditis secondary to vancomycin, daptomycin, and dalbavancin nonsusceptible MRSA. Resistance was associated with walK and scrA mutations, reduced long-chain lipid content, and reduced membrane fluidity.

Medical subject headings